Skip to main content
. 2023 Jul 6;9:228. doi: 10.1038/s41420-023-01515-w

Fig. 2. Gal-9 is cytotoxic for patient-derived AML cells but not CD34+ cord blood-derived cells.

Fig. 2

A Images of Gal-9-treated patient-derived AML, including MNC AML, CD34+ AML, and CD34− AML cells (light microscopy). Dose-dependent cytotoxicity of Gal-9 in liquid culture (1–3 days) for patient-derived AML cells in either the B MNC AML, C CD34+ AML, or D CD34− AML cell fraction. E Pictures of CD34+ patient-derived AML cells treated with Gal-9 (150, 300 nM) and CQ (20, 50 µM) for 4 days on top of an MS5 monolayer (light microscopy). Short-term (16 h) treatment of F patient-derived CD34+ or G CD34− AML cells on an MS5 stromal layer using the indicated concentrations of Gal-9. H Pictures of CD34+ patient-derived AML cells treated with Gal-9 (150, 300 nM) and CQ (20, 50 µM) for 4 days on top of an MS5 monolayer (light microscopy). Long-term incubation (5–7 days) of I CD34+ AML or J CD34+ CB cells on top of an MS5 stromal layer with the indicated doses of Gal-9 and evaluated using flow cytometry-based counts.